36847-11-7

Basic information

• Product Name: 2,4,6-TRIBROMOPYRIMIDINE
• Synonyms: 2,4,6-Tribromopyrimidine ,97%;6-tribroMopyriMidine;2,4,6-Tribromopyrimidine 95%
• CAS NO: 36847-11-7
• Molecular Formula: C₄HBr₃N₂
• Molecular Weight: 316.78
• Product Categories: Pyrimidine
• Mol File: 36847-11-7.mol

Chemical Properties

• Melting Point: 108-113°C
• Boiling Point: 369.1 °C at 760 mmHg
• Flash Point: 177 °C
• Appearance: /
• Density: 2.545 g/cm³
• Vapor Pressure: 2.58E-05mmHg at 25°C
• Refractive Index: 1.652
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: -7.31±0.30(Predicted)
• CAS DataBase Reference: 2,4,6-TRIBROMOPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,6-TRIBROMOPYRIMIDINE(36847-11-7)
• EPA Substance Registry System: 2,4,6-TRIBROMOPYRIMIDINE(36847-11-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41-36/37/38
• Safety Statements: 26-39-36/37/39-22
• WGK Germany: 3
• Hazardous Substances Data: 36847-11-7(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C4HBr3N2/c5-2-1-3(6)9-4(7)8-2/h1H

Upstream product

• 67-52-7 BARBITURIC ACID 

Downstream Products

• 60186-89-2 4-bromo-2,6-dimethoxy-pyrimidine 
• 70523-27-2 2,4-bis(benzyloxy)-6-bromopyrimidine 
• 1254697-47-6 6-bromo-2-morpholino-N-(6-phenoxypyridin-3-yl)pyrimidin-4-amine 

Relevant articles and documents

AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS

The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

Synthesis and in vitro and in vivo evaluation of phosphoinositide-3-kinase inhibitors

Phospoinositide-3-kinases (PI3K) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. A series of 2-morpholino, 4-substituted, 6-(3-hydroxyphenyl) pyrimidines have been reported as potent inh

Identification of NVP-BKM120 as a potent, selective, orally bioavailable class i PI3 kinase inhibitor for treating cancer

Phosphoinositide-3-kinases (PI3Ks) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent. The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma). These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clinical trials for the treatment of cancer.

PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS

Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof ; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

Total synthesis of (-)-7-epicylindrospermopsin, a toxic metabolite of the freshwater cyanobacterium Aphanizomenon ovalisporum, and assignment of its absolute configuration

(Chemical Equation Presented) The Z and E nitrones 38 and 39 from condensation of aldehyde 20 with hydroxylamine 36 underwent intramolecular dipolar cycloaddition to give the substituted 1-aza-7-oxobicyclo[2.2.1] heptanes 40 and 41 in a ratio of 2:1, respectively. Reductive N-O bond cleavage of 40 followed by carbonylation gave cyclic urea 47 in which inversion of the secondary alcohol was effected via an oxidation-reduction sequence. After conversion of the p-bromobenzyl ether 50 to azide 54, activation of the cyclic urea as its O-methylisourea and reduction of the azide led to spontaneous cyclization to afford the tricyclic nucleus 59 of cylindrospermopsin. Global deprotection, including hydrolysis of the 2,4-dimethyoxypyrimidine appendage to a uracil, and then monosulfation of the resultant diol 60 afforded a substance identical with natural (-)-7-epicylindrospermopsin (1). The asymmetric synthesis of (-)-7-epicylindrospermopsin defines its absolute configuration as 7S,8R,10S,12S,13R,14S.

Asymmetric synthesis of epicylindrospermopsin via intramolecular nitrone cycloaddition. Assignment of absolute configuration

A synthesis of (-)-epicylindrospermopsin (2) was completed that establishes its absolute configuration and corroborates the corrected structural assignment previously made to this toxin by Weinreb et al. The hydroxylamine 3, prepared from 4-bromobenzyloxy

Flame-resistant polycarbonates containing units deriving from halogenated pyrimidine compounds in their polymer chain

Flame-resistant thermoplastic branched polycarbonates of high molecular weight are prepared from: (1) a carbonate precursor; (2) at least one dihydroxyaromatic compound of formula: where:, R is a single bond, or a substituted or non-substituted linear or branched C1-C5 alkylene radical, or a group chosen from O, S, SO2 and CO;, X and Y, which may be the same or different, are H or CH3;, m and n, which may be the same or different, are whole numbers from 1 to 4; (3) at last one halogenated pyrimidine compound of formula: where: R2, R3, R4, which may be the same or different, are chlorine or bromine or hydrogen, on condition that at least one is chlorine or bromine;, R1 is chlorine or bromine, or a radical of formula: where Z is NH or S or O; (4) at least one polyfunctional organic compound as branching agent, characterized by possessing at least three equal or different groups chosen from the groups OH, COOH, COCl and SO2Cl.